Диссертация (1139475), страница 35
Текст из файла (страница 35)
Discordant Resistance to Kanamycin and Amikacin in Drug-238Resistant Mycobacterium tuberculosis// Antimicrobial Agents andChemotherapy. – 2003. – Vol. 47. - №9. – P. 2971 - 2973.372. Kuaban, C. et al. High effectiveness of a 12-month regimen for MDR-TBpatients in Cameroon. J Tuberc. 19, 517–524 (2015).373. Kuksa, L. et al. Multi- and extensively drug-resistant tuberculosis in Latvia:Trends, characteristics and treatment outcomes. PublicHealth Action.
4, S47–S53 (2014).374. Kurbatova E. V. et al. Predictors of poor outcomes among patients treated formultidrug-resistant tuberculosis at DOTS-plusprojects. Tuberculosis. 92, 397–403 (2012).375. Kurniawati F. Adverse drug reaction of primary anti-tuberculosis drugsamong tuberculosis patients treated in chest clinic / F.
Kurniawati, S. A. S.Sulaiman, S. W. Gillant // Int J Pharm Life Sci. -2012. – Vol. 3. – №1. – Р.1331–38.376. Kurosawa H. Studies on the antibiotic substances from actinomyces. XXIII.The isolation of an antibiotic produced by a strain of streptomyces “K 300”//J .Antibiot. Ser. B. - 1952. - Vol. 5. – P. 682.377. Kushner S., Dalalian H., Sanjuro J.L. et al. The synthesis of pyrazinamidesand related compounds// J.
Am. Chem. Soc. – 1952. – Vol. 74. – P. 3617 3621.378. Kvasnovsky C. et al. Extensively drug-resistant TB in Eastern Cape, SouthAfrica: High mortality in HIV-negative and HIV-positivepatients. J AcquirImmune Defic Syndr. 57, 146–152 (2011).379. Kwak N. et al. Changes in treatment outcomes of multidrug-resistanttuberculosis. J Tuberc.
19, 525–530 (2015).380. Lalloo U.G., Naidoo R., Ambaram. Recent advances in the medical andsurgical treatment of multi-drug resistant tuberculosis // A. Curr. Opin. Pulm.Med. – 2006. - № 12. - Suppl. 3. – Р. 179-85.381. Lalor M.
K. et al. Risk factors associated with default from multi- andextensively drug-resistant tuberculosis treatment, Uzbekistan: a retrospective239cohortanalysis.PLoSONEElectronResour.8,e78364,https://doi.org/10.1371/journal.pone.0078364 (2013).382. Larsen M.H. et al. Overexpression of inhA, but not kasA, confers resistanceto isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG andM.
tuberculosis // Mol. Microbiol. - 2002. – Vol. 46. – P.453 - 466.383. Laserson K. F. et al. Speaking the same language: treatment outcomedefinitions for multidrug-resistant tuberculosis // J. Tuberc. – 2005. – Vol. 9. –P. 640–645.384. Lehmann J.Para-aminosalicylic acid in the treatment of tuberculosis // Lancet.–1946. - Vol. 1. – P. 115.385. Leimane V. et al.
Clinical outcome of individualised treatment of multidrugresistant tuberculosis in Latvia: a retrospective cohortstudy. Lancet. 365, 318–326 (2005).386. Libermann D., Moyeux M., Rist N. Experimental antituberculous activity ofcertain isonicotinic thioamides substituted on the nucleus // Comptes RendusHebdomadaires des Seances de L'Academie des Sciences. 1956, 242(17):21872189.387. Lorent N.
Incidence and risk factors of serious adverse events duringantituberculous treatment in Rwanda: a prospective cohort study / N. Lorent, O.Sebatunzi, G. Mukeshimana, J. Van den Ende, J. Clerinx // PLoS One. – 2011.– Vol. 6. – №5. – e19566 [Электронный ресурс] – Режим доступа: doi:10.1371/journal.pone.0019566.388. Loveday M. et al. Community-based care vs. centralised hospitalisation forMDR-TB patients, KwaZulu-Natal, South Africa.
J. Tuberc. 19, 163–171(2015).389. Man MA, Nicolau D. Surgical treatment to increase the success rate ofmultidrug-resistant tuberculosis. European Journal of Cardio-Thoracic Surgery2012; 42: 9–12.390. Marais E. et al. Treatment outcomes of multidrug-resistant tuberculosispatients in Gauteng, South Africa. Infection.
42, 405–413(2014).240391. Marra F. Adverse drug reactions associated with first-line anti-tuberculosisdrug regimens / F. Marra, C.A. Marra, N. Bruchet, K. Richardson, S. Moadebi,R.K. Elwood, J. M. Fitzgerald // Int. J. Tuberc. Lung Dis. – 2007.
– Vol.11. ‒№8. ‒ P. 68‒75.392. Maus C.E., Plikaytis B.B., Shinnick T.M. Molecular analysis ofcrossresistance to capreomycin, kanamycin, amikacin, and viomycin inMycobacterium tuberculosis // Antimicrob. Agents Chemother. – 2005. – Vol.49. – P. 3192 - 3197.393. Mayer C, Takiff H. 2014. The Molecular Genetics of FluoroquinoloneResistance in Mycobacterium tuberculosis, p 455-478. In Hatfull G, Jacobs W(ed), Molecular Genetics of Mycobacteria, Second Edition.
ASM Press,Washington, DC. doi: 10.1128/microbiolspec.MGM2-0009-2013.394. Mdluli K. et al. Inhibition of a Mycobacterium tuberculosis bketoacylACPsynthase by isoniazid // Science. – 1998. – Vol. 280. – P. 1607-1610.395. Mdluli K.; Ma Zhenkun. Mycobacterium tuberculosis DNA Gyrase as aTarget for Drug Discovery // Infectious Disorders - Drug Targets (FormerlyCurrent Drug Targets - Infectious Disorders). – 2007. –Vol.7. - № 2.
– P. 159168(10).396. Meressa D. et al. Achieving high treatment success for multidrug-resistant TBin Africa: initiation and scale-up of MDR TB care inEthiopia–an observationalcohort study. Thorax. 70, 1181–1188 (2015).397. Migliori G. B., Loddenkemper R., Blasi F., Raviglione M.
C.. 125 yearsafter Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat.Is “science” enough to tackle the epidemic? // European Respiratory Journal. 2007. – Vol. 29. - №3. – P. 423-427.398. Miller A. C. et al. Alcohol use and the management of multidrug-resistanttuberculosis in Tomsk, Russian Federation.
J Tuberc. 16,891–896 (2012).241399. Mitchinson D.A. Early bactericidal activity and sterilizing activity ofciprofloxacin in pulmonary tuberculosis. (Correspondence) // Am. J. Respir.Crit. Care Med. – 1995. – Vol. 151. – P. 921.400. Mitchison D. The action of anti - tuberculosisdrugsinshort -course chemotherapy/ D. Mitchison // Tubercle. – 1985. – Vol.
66. – P. 219 –225.401. Mitchison D.A. How drug resistance emerges as a result of poorcompliance during short course chemotherapy for tuberculosis // Int. J.Tuberc. Lung Dis. –1998. – Vol. 2. – P. 10 -15;402. Mohsen T, Zeid AA, Haj-Yahia S. Lobectomy or pneumonectomy formultidrug-resistant pulmonary tuberculosis can be performed with acceptablemorbidity and mortality: a seven-year review of a single institution’sexperience. J Thorac Cardiovasc Surg 2007; 134: 194–98.403. Moore M., Onorato I.M., McCray E. et al. Trends in drug-resistanttuberculosis in the United States, 1993-1996 // JAMA. - 1997.
- Vol. 278. № 10. - P. 833-837.404. Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles intreatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474–81.405. Musser J. Antimicrobial agents resistance in mycobacteria: moleculargenetics insights / J. Musser // Clin. Microb. Rev. – 1995. – Vol. 8. – P. 496514.406. Nachega J. B., Chaisson R. E. Tuberculosis Drug Resistance: A GlobalThreat // Clinical Infectious Diseases. – 2003.
– Vol.36. - №1. – P. S24–S30.407. Naidoo R. Active pulmonary tuberculosis: experience with resection in 106cases. Asian Cardiovasc Thorac Ann 2007; 15: 134–38.408. Naidoo R., Reddi A. Lung resection for multidrug-resistant tuberculosis //Asian Cardiovasc Thorac Ann. – 2005. - Vol. 13. - №2. Р. 172-174.409. Nakajima Y. Surgical treatment of multidrug resistant pulmonarytuberculosis cases // Kekkaku. - 1997. - Vol. 72. - №1.
- P. 25-34.242410. NakajimaY.Surgicaltreatmentofpulmonarytuberculosis // Nippon Geka Gakkai Zasshi. - 2004. – Vol 105. - №12. - P. 745750.411. NakajimaY.Treatmentformultidrug-resistanttuberculosis in Japan // Kekkaku. – 2002. - Vol. 77. - №12. - P. 805-813.412. Nakano N., Hirayama T., Abe M., Nishimura K., Imachi T. Surgicalmanagement of non-tuberculous mycobacteriosis and tuberculosis of the lung //Kekkaku. – 2001. – Vol.
76. - №10. – P. 649-656.413. Nathanson E. Adverse events in the treatment of multidrug-resistanttuberculosis: results from the DOTS-Plus initiative / E. Nathanson, R. Gupta, P.Huamani, V. Leimane, A. D. Pasechnikov, T. E. Tupasi, K. Vink, E. Jaramillo,M. A. Espinal // Int J Tuberc Lung Dis. – 2004. – Vol. 8. – №11. – P. 1382–1384.414. Niimi S., Kato T., Hayakawa Y., Hirota M., Kako T.
Pulmonary surgery forpulmonary lesion with pulmonary tuberculosis or of tuberculosis // KyobuGeka. 2001. - Vol. 54. - №12. – Р. 1022-1024.415. Njire M., Tan, Y., Mugweru, J., Wang, C., Guo, J., Yew, W., Tan, S.,Zhang, T., Pyrazinamide resistance in Mycobacterium tuberculosis: review andupdate // Adv. Med. Sci. - 2016. – Vol. 61.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
